Table 2.
HIV-related characteristics assessed at baseline on all HIV-positive subjects
| ADC stage
|
|||||
|---|---|---|---|---|---|
| 0 N=124 |
0.5 N=66 |
1+ N=50 |
Total N=240 |
P-value | |
|
| |||||
| IV drug use, n (%) | 18 (15) | 21 (32) | 20 (40) | 59 (25) | 0.0001 |
|
| |||||
| HIV infection (years) | 0.093 | ||||
| Median (IQR) | 12.0 (7.0–17.2) | 11.0 (7.0–16.0) | 13.5 (10.0–17.0) | 12.0 (7.0–17.0) | |
|
| |||||
| CD4 count (cells/mm3) | 0.447 | ||||
| Median(IQR) | 312 (188–466) | 330 (215–510) | 269 (130–455) | 309 (187–471) | |
|
| |||||
| Nadir CD4 (cells/mm3) | 0.943 | ||||
| Median(IQR) | 31 (12–82) | 49 (19–83) | 22 (7–90) | 34 (12–84) | |
|
| |||||
| Plasma viral load (n=235) | 0.453 | ||||
| Undetectable, n (%) | 96 (79) | 47 (72) | 34 (71) | 177 (75) | |
|
| |||||
| CSF viral load (n=96) | 0.208 | ||||
| Undetectable, n (%) | 24 (62) | 19 (73) | 25 (81) | 68 (71) | |
|
| |||||
| Known on ART at baseline, n (%) | 112 (90) | 58 (88) | 49 (98) | 219 (91) | 0.140 |
|
| |||||
| Anti-HIV drug class, n (%) | 0.019 | ||||
| ART unknown | 12 (10) | 8 (12) | 1 (2) | 21 (9) | |
| ART including PI | 66 (53) | 42 (64) | 34 (68) | 142 (59) | |
| ART without PI | 40 (32) | 13 (20) | 8 (16) | 61 (25) | |
| Other combination | 6 (5) | 3 (5) | 7 (14) | 16 (7) | |
|
| |||||
| CPE score (n=220) | 0.501 | ||||
| Median(IQR) | 1.5 (1.0–2.5) | 1.5 (1.0–2.5) | 1.5 (1.5–2.5) | 1.5 (1.0–2.5) | |